Last time company raised cash price, was driven from 4 to 20 cents to raise at 17 cents. None of that trading apparently in the moment.
Quite to the contrary,, whilst company extended staff domestically as well as in US, added to pipeline, broadened IP listing of patents, price was capped and held low for period of negotiations. Ever since we presented in the US our stock price was controlled and brought down methodically to create entry price for partner.
The willingness of management to enlarge staff and pipeline regardless of financial restrictions points to knowledge not shared with market. Rohan though amply hinted at such in his recent presentation.
FDA approval will open the doors to several meaningful developments, all IMO
PYC Price at posting:
7.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)